Skip to main content
Fig. 1 | Infectious Diseases of Poverty

Fig. 1

From: Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021

Fig. 1

Number of 3-month standard DAAs treatment and reported cases of hepatitis C (Q3 2017–Q4 2021). ASV asunaprevir, CLP coblopasvir, DAC daclatasvir, DNV danoprevir, DSV dasabuvir, GLE/PIB Glecaprevir/Pibrentasvir, GZR/EBR Grazoprevir/Elbasvir, OPr Ombitasvir/Paritaprevir/Ritonavir, PR pegylated interferon alfa/ribavirin, r ritonavir, RAV ravidasvir, RBV ribavirin, SOF sofosbuvir, SOF/LDV sofosbuvir/ledipasvir, SOF/VEL sofosbuvir/velpatasvir, SOF/VEL/VOX sofosbuvir/velpatasvir/voxilaprevir

Back to article page

Infectious Diseases of Poverty

ISSN: 2049-9957

Contact us